Dr James Dear is the lead author of the article titled “Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial)” Dr. James Dear is an internationally leading expert in the treatment of paracetamol poisoning and was the principal investigator of the proof of principle phase Ib/IIa study conducted at the Royal Infirmary of Edinburgh and The Queen’s Medical Research Institute, the University of Edinburgh.

“In this clinical study we explored the safety and tolerability of Aladote® co-treatment with N-acetylcysteine (NAC – the only current treatment option). The combination of NAC and Aladote® was safe and tolerated. There was evidence from measurement of conventional and exploratory biomarkers that this combination treatment may reduce liver injury more than NAC alone after paracetamol overdose. There is a clear unmet need for a new treatment for paracetamol overdose because NAC is largely ineffective when given more than 8 hours after the overdose and there is no other medicine available to prevent acute liver failure. Aladote® is the only medicine in this clinical space and this trial demonstrates its potential as an effective new therapy.” says Dr James Dear.

“We are pleased to learn that Lancet has chosen to publish the Aladote® proof of principle-study and its results. The Lancet EBioMedicine sets very high standards for publishing and selects only the most important research results based on its quality and scientific impact. An article in a Lancet journal contributes to the awareness of Aladote® and strengthens our future opportunities. The need for improved treatment of paracetamol poisoning is important and it is our goal to meet this need with Aladote®. ” says Nicklas Westerholm, CEO of PledPharma.

EBioMedicine is a biomedical open access journal, published by The Lancet.

Follow this link30448-7/fulltext) to the article in the Lancet’s EBioMedicine.